Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice - Wikidata - awgldk - TriplyDB

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

http://www.wikidata.org/entity/Q24671899

about

Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine.Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis Leishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune response In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice.Treatment of visceral leishmaniasis.Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review.Clinical and experimental advances in treatment of visceral leishmaniasis.Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis.Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.Leishmanicidal activity of edelfosine, miltefosine and ilmofosine.Oral miltefosine for the treatment of Indian visceral leishmaniasis.Methods of Control of the Leishmania infantum Dog Reservoir: State of the Art.Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.Miltefosine: an oral drug for visceral leishmaniasis.Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice.Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites.Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.Preclinical Studies Evaluating Subacute Toxicity and Therapeutic Efficacy of LQB-118 in Experimental Visceral Leishmaniasis.Leishmaniasis treatment--a challenge that remains: a review.Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis.Liposomal resiquimod for the treatment of Leishmania donovani infection.Post-kala-azar dermal leishmaniasis--an overview.Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine.Drug target identification in protozoan parasites.Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.Chemotherapy of leishmaniasis: present challenges.Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica.Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp.Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by Leishmania donovani.Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes.In vitro prediction of human intestinal absorption and blood-brain barrier partitioning: development of a lipid analog for micellar liquid chromatography.Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions.

P2860

Q24538777-582715C0-9EF4-41FD-9537-2DAD043F9F00 Q27930460-238DD074-18D0-4BC6-A737-1145A81972B0 Q28073426-ACF37EDF-3931-4A2B-9E4C-F2B36A85FE58 Q28088410-55650ED7-40D4-4A52-896E-32FCF3A192D9 Q28271849-F82CE6C1-3A28-4720-BC57-89A41755C85E Q28481520-04F4E2D7-8607-48BB-A1C1-663F1435A4C5 Q28482212-0F55F0AE-B0B1-4365-98DB-3A1AD627B311 Q33691395-7C437F9C-7866-48DB-804C-F777305C4414 Q33929849-E3654F43-D848-4B83-A6AB-1812E2BB0903 Q33955466-DF973865-7C3F-4F8C-8400-BDB99E51D604 Q33982648-9F23FCED-F646-404A-A67C-CDADAEDC3EE2 Q34069469-C4540266-4103-468B-A6A4-AEF4E9648AF9 Q34289958-276BE228-311B-4AE3-ADEF-53C5EB19728C Q34387541-ED314816-0BDF-46F2-BCD4-76D5204ED35B Q34531203-49EFFD39-418A-49C7-87D1-3211E0E1B94C Q35101238-C64D8F7B-1120-4974-878D-931B818D660B Q35606296-A59846E3-3235-4531-8C4E-AAD78E9DD5D5 Q35724996-582F7041-BDF8-47FB-B805-AD6898B3FC6D Q35741989-4223EA5D-670E-4078-AC31-A3DE045DB355 Q36237748-79B00554-61CF-4555-8F3A-D135613F33B8 Q36564101-77E92470-E7EC-4EC6-8AFD-5A895442E49E Q36576096-29ACD08F-87D5-418B-B256-6E4183B293B1 Q36645795-774219F7-54A2-43E0-B933-5D46F83DBCCF Q36933386-66CEE2B4-38E1-4B4C-84EE-B8FDBF3DF8AD Q37128817-F1D7E030-8F6A-4730-9C21-E8BADBB1F704 Q37378031-A36C1112-AD02-4C5B-951F-2CAB44593596 Q37388288-238B6941-339B-42B4-A1EB-5064A4827756 Q37815533-450DE90D-7BD9-453D-9B5C-731E5ED7F540 Q38458645-2CAA79DC-A41F-45FA-B114-FF5C7D90A286 Q38847814-8BDF2D79-3BC1-40AE-B342-20095A3F6247 Q38994980-FCAB7CD2-6249-4C4F-B7D9-BDA979037CE4 Q39011875-F74B10B5-7949-409B-A668-0EB1068D01B3 Q39262349-3E8094F9-40C8-4740-845F-5C4F1B6C2620 Q39444318-D48CA69C-6CFA-405C-9A75-35DD30027146 Q39653044-B7041CAA-98C5-4ECF-A747-B7B3F4F7042D Q40460848-1DC209DD-C68A-4016-8259-A3CCE84D262C Q40541880-13E3F2C5-35BC-4C06-A658-DC021051DBC2 Q40622211-4B49396F-F2A0-4435-9443-A8C29A51D294 Q40639437-7B5EF833-F445-4A0F-8AB5-C48A9B42F6FB Q41893418-92EF938F-0B17-446B-B836-C5C78FED3D13

P2860

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

http://www.wikidata.org/entity/Q24671899

description

1992 nî lūn-bûn

@nan

1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1992 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1992年の論文

@ja

1992年学术文章

@wuu

1992年学术文章

@zh-cn

1992年学术文章

@zh-hans

1992年学术文章

@zh-my

1992年学术文章

@zh-sg

1992年學術文章

@yue

name

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

@ast

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

@en

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

@nl

type

label

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

@ast

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

@en

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

@nl

prefLabel

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

@ast

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

@en

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

@nl

P1433

Q24671899-DA6970C9-7946-4A84-9F62-CF0F81501DD3

P1476

Q24671899-CB59F634-A39E-4240-89E0-C5173BA0D142

P2093

Q24671899-952A1ED8-7C02-4A8C-B923-477F55F430F3

Q24671899-D8BDEA08-13FA-404C-87F7-29706F31EA33

Q24671899-F4846109-60BD-430C-BCBD-16A578E55920

Q24671899-FD8B35FF-565E-4632-93AC-455B03A86ADC

P2860

Q24671899-0FECE736-4B19-4944-8EC5-CCBC550D6DF9

Q24671899-295565E8-F8B9-49FB-B3CA-1D22EB391CEB

Q24671899-5C6E7BF3-64F1-4429-9759-59B1F17DC37D

Q24671899-62561375-3BEE-4EB2-8796-9AA95F033ED4

Q24671899-74231B34-436F-4A9B-A34C-DE6859E4383A

Q24671899-86A50423-0845-47B9-824B-A783E253F1D5

Q24671899-9BC72A5E-6220-40AA-BE54-2CBE381DEE76

Q24671899-B0184A22-EC42-42D3-8DA7-D16A3C8899F8

Q24671899-B40553FE-92E4-47D3-885F-0118A096D59F

Q24671899-BA84C6CD-78A4-412C-B84F-F97C7A4B3337

P304

Q24671899-8BEB6EA9-606D-448C-80CA-CA1AC7BB468A

P31

Q24671899-DA5ECA4A-5E18-4504-A07B-E19C3D53FB77

P356

Q24671899-E76560C9-3B6A-4477-8AA9-82977644B8F2

P407

Q24671899-914E8B33-16DC-44FC-A6F8-8D0DEA95E73F

P433

Q24671899-89D4ADF8-0F18-4A02-BCF2-984F2C33D86E

P478

Q24671899-7DF6ADAE-1098-4FCE-87C4-EC3FA7404B75

P577

Q24671899-60566B06-19B8-4C83-A018-11AFDB690856

P698

Q24671899-F9B3BD73-6E3B-4792-91F7-773304EEF492

P921

Q24671899-929E395A-0EAF-4CA4-A361-E116748252D6

P932

Q24671899-51A9C969-5273-4D09-AA13-DB88F77CD5BB

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

@en

P2093

A Kuhlencord

http://www.w3.org/2001/XMLSchema#string

C Unger

http://www.w3.org/2001/XMLSchema#string

H Eibl

http://www.w3.org/2001/XMLSchema#string

T Maniera

http://www.w3.org/2001/XMLSchema#string

P2860

Hexadecylphosphocholine: a new and selective antitumor drug

Characterization of the antitumor activity of hexadecylphosphocholine (D 18506)

The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani

Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis

Antileishmanial defense in macrophages triggered by tumor necrosis factor expressed on CD4+ T lymphocyte plasma membrane

Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy.

Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies.

Suppression of Leishmania donovani by oral administration of a bis(benzyl)polyamine analog.

The phospholipid analogue hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells.

P304

1630-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.36.8.1630

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

1992-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1329624

http://www.w3.org/2001/XMLSchema#string

P921

visceral leishmaniasis

P932

192021

http://www.w3.org/2001/XMLSchema#string